Supreme Curveball: Abortion Pill Fight Isn’t Over

Anti-abortion groups have spent years trying to ban the abortion pill nationwide through federal courts — but a unanimous Supreme Court just shut them down on a key legal point, and more lawsuits are still in the pipeline.

Story Snapshot

The Supreme Court ruled in June 2024 that anti-abortion doctors lacked the legal standing to challenge the Food and Drug Administration’s approval of mifepristone.
At least three separate federal lawsuits target telehealth access to mifepristone, meaning the legal fight is far from over.
The cases raise a bigger question: should federal drug regulators or state lawmakers control abortion policy?
A ruling that restricts mifepristone nationwide could affect not just abortion but also miscarriage treatment and pharmacy practice.

The Supreme Court Shut Down One Challenge — But Not All of Them

In June 2024, the Supreme Court ruled unanimously that the plaintiffs in Alliance for Hippocratic Medicine v. Food and Drug Administration (FDA) did not have legal standing to bring their case. ^[1] That means the court never ruled on whether the FDA did anything wrong. The justices simply said these particular plaintiffs — a group of pro-life doctors and medical groups — could not show they were directly harmed by the FDA’s approval of mifepristone. The drug stayed on the market.

Standing is a legal requirement. To sue in federal court, you must prove you were personally harmed. The Supreme Court found these doctors could not meet that bar. ^[9] That sounds like a win for the status quo — and in the short term, it was. But it also means no court has actually ruled on whether the FDA followed the law when it approved mifepristone or later expanded access to it. Those underlying questions remain open.

Three More Lawsuits Are Still Active

While the Alliance for Hippocratic Medicine case got the most attention, it is not the only one. At least three federal lawsuits brought by anti-abortion state officials are pushing to block telehealth access to mifepristone. ^[2] Louisiana v. FDA is one of them. These cases argue that prescribing the drug over video calls and mailing it to patients violates federal law. The Trump administration has responded to at least one of these suits, keeping the legal fight alive. ^[4]

UCLA Law’s Mifepristone Litigation and Federal Action Tracker lists 12 cases that could affect access to mifepristone, with 8 still active. ^[3] These cases come from different angles — some challenge the FDA’s original approval, others target the relaxed rules on how the drug is distributed. Together, they form a broad legal campaign aimed at restricting the drug through federal courts rather than through state legislatures.

Why This Matters Beyond the Abortion Debate

Mifepristone sits at the center of several overlapping legal fights. It involves FDA drug-approval authority, telemedicine rules, mail pharmacy distribution, and state abortion enforcement all at once. ^[3] That makes this more than just an abortion issue. Mifepristone is also used to treat miscarriages. A nationwide court-ordered restriction could disrupt care for women who are not seeking abortions at all.

Conservatives who believe abortion policy should be decided at the state level — not by unelected federal judges or federal regulators — have reason to watch these cases carefully. The lawsuits are not trying to pass a law through Congress or a state legislature. They are asking federal courts to override an FDA decision and restrict a drug across all 50 states. That is a major use of federal power, and it cuts against the principle that voters and their elected representatives should set abortion policy. However the abortion debate lands for any individual conservative, the method here deserves scrutiny.